Tasso Unveils Next-Generation Blood Collection Devices for Remote Clinical Trials

Tasso, a leading manufacturer of at-home blood sample collection systems, has launched its latest generation of devices aimed at revolutionizing patient participation in clinical trials and drug development. The new hardware, designed for dried blood spot collection, promises to enhance the efficiency of remote clinical trials and simplify the process for study participants.

Innovative Technology for Precise Sample Collection

The centerpiece of Tasso's new offering is the Tile-T20 cartridge, accompanied by the wearable Tasso Mini push-button lancet. These devices are engineered to collect four precise blood samples at a specific volume, addressing a critical need in biopharma research and drug development. The technology enables researchers to accurately measure medication concentrations and establish appropriate dosages without requiring patients to visit clinical sites.

Ben Casavant, Ph.D., co-founder and CEO of Tasso, highlighted the advantages of the new system: "Dried blood samples offer many advantages for clinical trials and remote applications, but collection methods have long been a burden on patients, relying on painful finger sticks and messy blood spotting to obtain samples. Our next generation dried blood collection systems enable a better patient experience alongside new process improvements."

Expanding Applications and Regulatory Approval

While the Tile-T20 cartridge is CE marked for use in Europe, it is currently designated for research use only within the United States. The device provides redundant, 17.5-microliter samples of dried blood that can be shipped and stored at room temperature, offering significant logistical benefits for clinical trials.

Tasso's innovative approach extends beyond clinical trials, with potential applications in sports anti-doping testing. This versatility underscores the broad impact of the company's technology on various sectors requiring precise blood sample collection.

The launch of these new devices builds upon Tasso's previous successes, including regulatory approvals in both the United States and Europe for its Tasso Mini and Tasso+ systems. These earlier innovations demonstrated the company's ability to develop devices that can collect whole blood samples at larger liquid volumes, which can be easily mailed to laboratories for analysis.

Addressing Clinical Trial Challenges

Erwin Berthier, Ph.D., Tasso's co-founder and chief technology officer, emphasized the potential impact of this technology on clinical trial timelines: "Access to clinic sites can be difficult for many patients, especially for those without reliable transportation or living in rural areas. Unfortunately, access challenges often lead to recruitment and retention issues, ultimately delaying clinical trial timelines. This new technology has the potential to improve trial timelines and speed new therapies to patients in need."

By enabling remote sample collection, Tasso's devices address a significant hurdle in clinical trial participation, potentially accelerating the drug development process and bringing new treatments to market more quickly.